{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:37:56Z","timestamp":1759178276281},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T00:00:00Z","timestamp":1474934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Sofosbuvir\/ledipasvir (<jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LDV<\/jats:styled-content>) is the first all\u2010oral ribavirin\u2010free treatment approved for chronic hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) genotype 6, offering a safe and highly efficacious treatment option. Large studies evaluating real\u2010world outcomes of this regimen are lacking. We aim to evaluate real\u2010world treatment outcomes for <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 6. A retrospective cohort study evaluated 65 adults (age \u226518) with chronic <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 6 treated with <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LDV<\/jats:styled-content> without ribavirin at a community gastroenterology clinic in the United States from November 2014 to May 2016. Rates of undetectable virus at week 4 on treatment, at end of treatment (<jats:styled-content style=\"fixed-case\">EOT<\/jats:styled-content>) and <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12 were stratified by the presence of cirrhosis and prior treatment (treatment na\u00efve vs treatment experienced). Among 65 patients with chronic <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 6 treated with <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LDV<\/jats:styled-content> (52.3% male, mean age 66.3\u00a0years [<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content> 9.7], 41.5% cirrhosis and 15.4% treatment experienced), 97.3% had undetectable virus at week 4 on treatment, 96.9% had undetectable virus at <jats:styled-content style=\"fixed-case\">EOT<\/jats:styled-content> and 95.3% achieved <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12. <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12 was 100% in females vs 91.2% in males, <jats:italic>P<\/jats:italic>=.096, and 92.3% in patients with cirrhosis vs 97.4% in those without cirrhosis, <jats:italic>P<\/jats:italic>=.347. Resistance testing of treatment failures was attempted but unsuccessful due to lack of conforming primers to define the possible resistance mutations. Among the largest U.S. community\u2010based real\u2010world cohort of Asian chronic <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 6 patients treated with all\u2010oral <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LDV<\/jats:styled-content> without ribavirin, <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12 was similar to <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12 reported in clinical trials, confirming the safety and effectiveness of this regimen and validating current <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 6 treatment guideline recommendations.<\/jats:p>","DOI":"10.1111\/jvh.12609","type":"journal-article","created":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T03:43:51Z","timestamp":1475034231000},"page":"17-21","source":"Crossref","is-referenced-by-count":15,"title":["Community\u2010based real\u2010world treatment outcomes of sofosbuvir\/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States"],"prefix":"10.1111","volume":"24","author":[{"given":"R. J.","family":"Wong","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology Alameda Health System \u2013 Highland Hospital  Oakland CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. T.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Silicon Valley Research Institute  San Jose CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. N.","family":"Trinh","sequence":"additional","affiliation":[{"name":"San Jose Gastroenterology  San Jose CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Huynh","sequence":"additional","affiliation":[{"name":"Silicon Valley Research Institute  San Jose CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. T.","family":"Ly","sequence":"additional","affiliation":[{"name":"Silicon Valley Research Institute  San Jose CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. A.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"San Jose Gastroenterology  San Jose CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. K.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"San Jose Gastroenterology  San Jose CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Yang","sequence":"additional","affiliation":[{"name":"San Jose Gastroenterology  San Jose CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. T.","family":"Garcia","sequence":"additional","affiliation":[{"name":"San Jose Gastroenterology  San Jose CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Levitt","sequence":"additional","affiliation":[{"name":"San Jose Gastroenterology  San Jose CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"da Silveira","sequence":"additional","affiliation":[{"name":"San Jose Gastroenterology  San Jose CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. G.","family":"Gish","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Stanford Health Care  Stanford CA USA"},{"name":"National Viral Hepatitis Roundtable  San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,9,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26218"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.11.039"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26986"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7085"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.6011"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27736"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23889"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.020"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_7_13_1","unstructured":"AASLD\u2010IDSA.Recommendations for testing m and treating hepatitis C.2016.www.hcvguidelines.org. Accessed June 10 2016."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.063"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0785"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12609","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12609","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T14:43:33Z","timestamp":1696171413000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,27]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/jvh.12609"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12609","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,27]]}}}